Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C β-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial

This publication has 65 references indexed in Scilit:

• Lower-extremity amputation in diabetes. The independent effects of peripheral vascular disease, sensory neuropathy, and foot ulcers.
  Diabetes Care, 1999
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
  The Lancet, 1998
• A Multicenter Study on the Prevalence of Diabetic Neuropathy in Italy
  Diabetes Care, 1997
• Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM Complications Study
  Diabetologia, 1996
• The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus
  New England Journal of Medicine, 1993
• The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population‐based cohort
  Neurology, 1993
• A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population
  Diabetologia, 1993
• Risk Factors for Amputation in Patients with Diabetes Mellitus
  Annals of Internal Medicine, 1992
• Epidemiological correlates of diabetic neuropathy. Report from Pittsburgh Epidemiology of Diabetes Complications Study
  Diabetes, 1989
• Factors in development of diabetic neuropathy. Baseline analysis of neuropathy in feasibility phase of Diabetes Control and Complications Trial (DCCT). The DCCT Research Group
  Diabetes, 1988